[Show abstract][Hide abstract] ABSTRACT: Bangladesh has the highest level of incidence and mortality rates due to cervical cancer among women. The prevalence of cervical cancer in Bangladeshi women is 25-30/100,000. Human papillomavirus is an important cause of cervical cancer. The study was conducted to assess the immunogenicity and safety profile of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccines in healthy Bangladeshi girls aged 9-13 years. Procedure This was a randomized (3:1) controlled trial with two parallel groups, the vaccine and control groups, that included 67 participants in Bangladesh. Subjects were given GlaxoSmithKline human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine (and controls no vaccine) at the first day of vaccination (Day 0), at 1- and 6-month schedule and followed up until 7 months. Blood samples were taken for human papillomavirus antibody at enrollment and 1 month post-schedule at Month 7 from both subjects and controls. Safety data were gathered throughout the study period.
Fifty subjects received vaccine at Day 0, 1 month and 6 months. All subjects were initially sero-negative in the vaccine group, and developed sero-conversion for human papillomavirus-16 and -18 antibodies except for one at Month 7. Seventeen controls did not receive vaccine. Clients were followed up for serious medically important events and blood samples were taken for human papillomavirus antibody detection at Day 0 and Month 7. Sero-conversion was found in 97.5% of subjects and no sero-conversion was found in the controls. Bivalent human papillomavirus vaccine was generally well tolerated, with no vaccine-related serious adverse experiences.
The human papillomavirus-16/18 AS04-adjuvanted vaccine was generally well tolerated and highly immunogenic when administered to young adolescent females and could be a promising tool for the prevention and control of cervical cancer in Bangladesh.
Japanese Journal of Clinical Oncology 01/2012; 42(1):36-41. · 1.90 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Cervical cancer is the most common cancer among women in many developing countries constituting 20%-30% of female cancers. The etiological factors of cervical cancer include environmental, social, sexual and sexually transmitted agents including human papilloma virus (HPV).HPV has identified in 99.7% invasive cancer .Objective of the study was to find out the prevalence of HPV-DNA virus among diagnosed cases of preinvasive and invasive diseases and to find out different sociodemographic parameters related to carcinoma cervix. This was a cross sectional study. The study has conducted in the department of Obstetrics and Gynaecology of Bangabandhu Sheikh Mujib Medical University. Duration of study was from May 2005 to May 2006. Samples were collected from diagnosed cases of CIN I, II, III and CIS and invasive cancer. Thirty cases were recruited for collection of cervical scraping. Sample were collected of in a specially designed sampler containing liquid transport medium and preserved in minus 20 Degree Celsius and sent to the DNA laboratory for processing and identification of HPV by hybrid capture II method. The results were analyzed by using SPSS version 11.0 and shown in tables and diagrams. The risk factors for HPV infection identified from the result. These are early sexual activity, years of sexual activity, urban people, and higher number of pregnancies. The test could identify HPV-DNA in 100 % of invasive and 50 % of preinvasive cancer. In this study HPV infection was found as a strong determinant for the development of cervical carcinoma and its precursors. Poor socio-economic condition, lower level of education, early marriage and first delivery, multi-parity, years of sexual activity are the risk factors for developing HPV infection. New guidelines for cervical cancer screening strategies could be able to develop from the information obtained from this study. A population-based study with larger sample will be required for the evaluation of cervical cancer screening strategies.